title: Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice.
abstract: Preclinical Research Rhizoma Coptidis (RC), the root of Coptis chinensis Franch, a species in the genus Coptis (family Ranunculaceae), has been commonly prescribed for the treatment of diabetes in Chinese traditional herbal medicine applications. The present study is focused on the assessment of the antihyperglycemia and antidiabetic hyperlipidemia effect of five protoberberine alkaloids, berberine (BBR), coptisine (COP), palmatine (PAL), epiberberine (EPI), and jatrorrhizine (JAT), separated from R. Coptidis in hepatocellular carcinoma HepG2 cells and diabetic KK-Ay mice. Protoberberine alkaloids are effective in modulating hyperglycemia and hyperlipidemia. After adding BBR and COP to culture medium, glucose consumption of HepG2 cells was increased. In KK-Ay mice assays, suppressed fasting blood glucose level and ameliorated glucose tolerance were observed after BBR/COP administration. After treated with berberine and coptisine, in the same dose of 5 µg/mL, the glucose consumption of HepG2 cells were promoted and, respectively, reached 96.1% and 17.6%. Body weight, food consumption, water intake, and urinary output of KK-Ay mice were reduced after treated with EPI. Serum total cholesterol and triglyceride of mice were decreased after treated with palmatine and jatrorrhizine. Serum high-density lipoprotein cholesterol of mice was increased after palmatine, jatrorrhizine, and berberine administrated. Moreover, hepatomegaly was attenuated in JTR-treated mice. Suggested that these protoberberine alkaloids from R. Coptidis have potential curative effect for diabetes. Drug Dev Res 77 : 163-170, 2016.   © 2016 Wiley Periodicals, Inc.
authors.affiliation: School of Pharmacy, Southwest University, Chongqing, 400716, China.
authors.forename: Hang
authors.initials: H
authors.lastname: Ma
authors.affiliation: School of Pharmacy, Southwest University, Chongqing, 400716, China.
authors.forename: Yinran
authors.initials: Y
authors.lastname: Hu
authors.affiliation: School of Pharmacy, Southwest University, Chongqing, 400716, China.
authors.forename: Zongyao
authors.initials: Z
authors.lastname: Zou
authors.affiliation: Chongqing Technology and Business University, Chongqing, 400067, China.
authors.forename: Min
authors.initials: M
authors.lastname: Feng
authors.affiliation: School of Life Science, Southwest University, Chongqing, 400715, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Ye
authors.affiliation: School of Pharmacy, Southwest University, Chongqing, 400716, China.
authors.forename: Xuegang
authors.initials: X
authors.lastname: Li
mesh_terms: D000818:Animals; D001600:Berberine Alkaloids / Q000302:isolation & purification / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D000089042:Coptis chinensis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D004365:Drugs, Chinese Herbal / Q000737:chemistry*; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000188:drug therapy; D051379:Mice; D010936:Plant Extracts / Q000494:pharmacology
chemical_list: D001600:Berberine Alkaloids; D004365:Drugs, Chinese Herbal; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010936:Plant Extracts; C009090:protoberberine; C107393:Coptidis rhizoma extract
keywords: Rhizoma Coptidis; hyperglycemia; hyperlipidemia; protoberberine